**Core Concept**
The management of arrhythmias in patients with interstitial lung disease (ILD) requires careful consideration of the potential effects of antiarrhythmic medications on respiratory function. The underlying concern is the risk of exacerbating ILD or inducing pulmonary fibrosis, especially with medications that have been associated with pulmonary toxicity.

**Why the Correct Answer is Right**
Amiodarone is a well-known antiarrhythmic medication that contains iodine and has been linked to pulmonary toxicity, including pulmonary fibrosis and pneumonitis. The risk of pulmonary toxicity is particularly concerning in patients with pre-existing ILD, as it can lead to severe respiratory compromise. Amiodarone's lipophilic nature allows it to accumulate in the lungs, increasing the risk of pulmonary toxicity.

**Why Each Wrong Option is Incorrect**
**Option A:** Propafenone is a class IC antiarrhythmic medication that is not typically associated with pulmonary toxicity. While it may have some side effects, it is not the primary concern in patients with ILD.
**Option B:** Sotalol is a class III antiarrhythmic medication that can cause pulmonary edema due to its beta-blocking effects, but it is not as strongly associated with pulmonary toxicity as amiodarone.
**Option C:** Flecainide is a class IC antiarrhythmic medication that is generally safe in patients with ILD and is not typically associated with pulmonary toxicity.

**Clinical Pearl / High-Yield Fact**
When managing arrhythmias in patients with ILD, it is essential to weigh the benefits of antiarrhythmic therapy against the potential risks of exacerbating pulmonary toxicity. Amiodarone should be avoided in these patients whenever possible, and alternative antiarrhythmic medications should be considered.

**Correct Answer:** C. Flecainide